Skip to Content

A Hidden Brain Disease May Soon Be Detectable Through a Simple Blood Test

For decades, former athletes have faced a frightening possibility: Years of repeated blows to the head could eventually lead to an incurable brain disease. Chronic traumatic encephalopathy (CTE) has been linked to memory loss, dementia, and changes in behavior, yet doctors have had no reliable way to confirm the condition while someone is alive. That could begin to change after researchers identified unusual proteins in the blood that may help detect the disease.

Two new studies published in the medical journal JAMA have raised hopes that a simple blood test could eventually help identify CTE in living patients. The findings are particularly significant for former football players and others exposed to repeated head injuries. Although the research remains preliminary, scientists believe the discovery could open a new path toward earlier diagnosis and future treatment development.

Two New Studies Offer Hope For Detecting CTE

Researchers have spent years investigating why some former athletes develop serious neurological problems after repeated blows to the head. CTE is a progressive brain disease associated with repeated head impacts, and its effects can include memory difficulties, dementia, and troubling behavioral changes. The condition has been identified among former football players, boxers, rugby players, and other individuals exposed to repeated head trauma.

Until now, confirming CTE has required an examination of brain tissue after death. Doctors can investigate symptoms during someone’s lifetime, but they cannot definitively establish whether those symptoms are caused by CTE. This limitation has left many families searching for answers while watching loved ones experience changes in their cognitive abilities and behavior.

The two new studies investigated abnormal forms of tau, a protein that normally helps maintain the structure and function of nerve cells. In people with CTE, abnormal tau proteins accumulate into clumps within specific areas of the brain. These deposits are associated with damage to nerve cells and progressive brain deterioration.

Researchers identified blood-based markers associated with these abnormal proteins. Both investigations suggest that measuring certain tau-related fragments could eventually help identify people with CTE. However, the studies involved relatively small groups, meaning larger investigations are necessary before doctors can rely on the findings.

How Researchers Discovered The Potential Blood Markers

The first study was led by researchers at Washington University School of Medicine. Their investigation began with an unexpected finding while examining more than 200 samples collected from healthy individuals and people with different neurological conditions. One sample contained an unusual protein fragment that attracted the researchers’ attention because the patient did not have an Alzheimer’s diagnosis.

When researchers examined the patient’s autopsy records, they discovered advanced CTE. This unexpected connection prompted the team to investigate whether the same protein could appear in other people with the condition. The protein fragment, known as eMTBR-tau243, had already been investigated in Alzheimer’s research because of its association with abnormal tau accumulation.

The researchers subsequently examined blood samples from 11 additional people whose CTE diagnoses had been confirmed after death. Their findings suggested that individuals with more advanced disease had higher levels of the protein. This association raised the possibility that the marker could help researchers identify CTE in living patients.

Dr. Chihiro Sato, an assistant professor of neurology and lead author of the study, described the unexpected discovery as an example of scientific serendipity. “It was just a matter of serendipity,” Dr. Sato said. She explained that the biomarker would not work as a stand-alone diagnostic tool, but it could become useful when doctors evaluate someone with a history of repeated head injuries.

A Second Study Found Similar Results In Former Football Players

The second investigation was led by researchers at the CTE Research Center at Boston University and Banner Health. It examined 21 former football players who had donated blood samples and brain tissue before their deaths. Eighteen participants were found to have CTE, allowing researchers to compare blood measurements with the severity of their disease.

The group included 12 former professional football players, seven former college players, and two individuals who had played football only during high school. Researchers discovered that participants with higher concentrations of abnormal tau protein in their blood plasma tended to have more advanced CTE. Those with lower-stage disease had little or no detectable amounts of the protein.

Dr. Michael Alosco, a senior author of the study and co-director of the CTE Research Center, described the difference between the groups as striking. “When we looked at the data, we saw that there was a very clear separation with almost no overlap in the data points between those with high-stage C.T.E. and everyone else,” Dr. Alosco said.

The results provide additional evidence that blood biomarkers could help researchers investigate CTE. However, the small sample size makes it difficult to determine how accurately the test would perform among thousands of people with different medical histories. Further research will need to establish whether the same pattern appears consistently across larger populations.

What CTE Does To The Brain

Chronic traumatic encephalopathy is associated with repeated head impacts that can occur during contact sports and other activities involving recurring brain trauma. Football, rugby, and boxing have received considerable attention because athletes can experience repeated impacts throughout their careers. Military personnel and victims of domestic violence can also experience repeated head injuries.

The Role Of Abnormal Tau Proteins

Tau proteins normally help support the internal structure of nerve cells. They play an important role in maintaining the systems that allow brain cells to function properly. In CTE, abnormal tau proteins accumulate in particular regions of the brain, forming deposits that can interfere with normal cellular processes.

These deposits are associated with nerve cell damage and brain atrophy. As the disease progresses, affected individuals may experience difficulties with memory, thinking, and behavior. The severity and progression of symptoms can vary, making the condition difficult to recognize during its early stages.

Why Diagnosis Has Been So Difficult

One major challenge is that CTE symptoms can overlap with those of other neurological conditions. Memory problems, cognitive difficulties, and behavioral changes can have several possible explanations. Alzheimer’s disease is particularly relevant because abnormal tau proteins are also associated with that condition.

This overlap makes it difficult for doctors to identify the underlying cause of symptoms using clinical observations alone. A reliable blood biomarker could provide another tool for investigating suspected cases. However, researchers must first determine how accurately these markers distinguish CTE from other neurological diseases.

Why A Blood Test Could Change Brain Health Research

The possibility of detecting CTE through a blood sample could have significant implications for former athletes and their families. People experiencing unexplained cognitive changes sometimes spend years seeking an explanation. Without a definitive diagnostic method, doctors may struggle to determine whether previous head injuries contributed to their symptoms.

A validated blood test could help researchers identify people who may have CTE while they are still alive. It could also improve the selection of participants for clinical studies, allowing scientists to investigate the disease more effectively. This could eventually help researchers understand which biological processes are responsible for disease progression.

Another potential benefit involves treatment development. Dr. Gil Rabinovici, a behavioral neurologist at the University of California, San Francisco, and one of the study authors, described reliable diagnosis as an essential first step toward attracting drug developers. He pointed to Alzheimer’s research, where improved diagnostic methods have helped researchers identify patients who may benefit from treatments.

Although several FDA-approved Alzheimer’s treatments can slow disease progression in certain early-stage patients, CTE currently has no established cure. Researchers still need to determine whether treatments can prevent or slow the damage associated with the condition. A reliable diagnostic test could help make those investigations more practical.

The Research Still Has Important Limitations

Despite the encouraging findings, scientists have emphasized that the results remain preliminary. Both studies involved relatively small groups of participants, and their findings must be replicated in larger populations. Researchers also need to establish how accurately the biomarkers identify CTE in people with different medical histories.

One important challenge involves distinguishing CTE from Alzheimer’s disease. Since both conditions can involve abnormal tau proteins, researchers must determine whether the blood markers provide enough information to separate the two conditions reliably. Without that distinction, a positive result could create confusion for patients and healthcare professionals.

Another obstacle involves detecting extremely small quantities of these proteins in blood samples. Dr. Nicholas Ashton, senior director of the Fluid Biomarker Program at Banner Health and another study author, explained the technical difficulty using an example involving a tiny piece of sugar in an Olympic-sized swimming pool. The comparison illustrated just how sensitive the testing technology needs to be.

Researchers hope their work could eventually lead to a commercially available blood test within approximately five years. However, that timeline depends on successful validation and further development. A promising research finding still needs extensive testing before it can become a dependable medical diagnostic tool.

What Former Athletes And Families Should Know

The findings are particularly relevant to people who have spent years participating in activities involving repeated head impacts. Former football players, rugby players, and boxers are among those who may have experienced repeated exposure to head trauma. Military personnel and people exposed to repeated physical violence can also face similar risks.

However, experiencing repeated head impacts does not automatically mean someone will develop CTE. Likewise, memory difficulties or behavioral changes do not establish that a person has the disease. Other neurological and medical conditions can produce similar symptoms, making professional evaluation important.

While researchers continue investigating diagnostic methods, people can take practical steps to reduce their exposure to further head injuries:

  • Take head injuries seriously: Seek appropriate medical evaluation after a suspected concussion or significant blow to the head.
  • Allow adequate recovery: Follow medical guidance before returning to contact sports or activities that could cause another injury.
  • Report persistent symptoms: Memory difficulties, dizziness, headaches, and concentration problems deserve medical attention.
  • Reduce repeated head impacts: Follow established safety practices during sports and physical activities.
  • Discuss previous injuries: Share your history of concussions and repeated head trauma with your healthcare professional.

People experiencing neurological symptoms should avoid assuming they have CTE based on symptoms alone. A healthcare professional can investigate other possible explanations and determine which evaluations may be appropriate.

Could The Next Five Years Transform CTE Diagnosis?

The researchers involved in the studies hope their findings will eventually lead to an accessible blood test. Their proposed timeline is around five years, although additional research will determine whether that goal is achievable. The development of a reliable test could help researchers investigate CTE much earlier than current diagnostic methods allow.

Dr. Marc Weisskopf, director of epidemiological studies at Harvard’s Football Players Health Study, urged people to approach the findings carefully. He described the biomarker as a potential research tool that could improve understanding of CTE and its effects on the brain. His caution reflects the difference between identifying a promising biological marker and establishing a dependable diagnostic test.

Researchers must still determine how accurately the test identifies CTE, how it performs across different populations, and whether other neurological conditions produce similar results. They also need to establish whether blood measurements can consistently reflect the severity of the disease. These questions will shape the next stage of research.

For families dealing with unexplained cognitive and behavioral changes, reliable answers could eventually make a significant difference. A test that helps identify CTE during someone’s lifetime could also give researchers a clearer way to investigate potential treatments.

A Better Way To Diagnose CTE Could Begin With One Blood Sample

For people who have spent years wondering whether repeated head injuries affected their brains, the possibility of a blood-based CTE test offers cautious hope. The two studies provide early evidence that abnormal tau proteins may help researchers identify the disease before death.

There is still substantial work ahead, and the findings should not be mistaken for an available diagnostic test. But if larger studies confirm the results, a simple blood sample could eventually help doctors answer questions that have remained unresolved for generations of athletes.

Loading...

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This site uses Akismet to reduce spam. Learn how your comment data is processed.